login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
NEKTAR THERAPEUTICS (NKTR) Stock News
USA
-
Nasdaq
- NASDAQ:NKTR -
US6402683063
-
Common Stock
60.65
USD
+2.01 (+3.43%)
Last: 11/25/2025, 3:02:48 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
NKTR Latest News, Press Relases and Analysis
All
Press Releases
19 days ago - By: Chartmill
Nektar Therapeutics (NASDAQ:NKTR) Q3 2025 Earnings Top Estimates, Sending Shares Higher
5 days ago - By: The Motley Fool
- Mentions:
CDTX
BMRN
MRK
Cidara Therapeutics Is Up Over 100%. Here's What Investors Need to Know.
12 days ago - By: Zacks Investment Research
Does Nektar (NKTR) Have the Potential to Rally 62.75% as Wall Street Analysts Expect?
17 days ago - By: Nektar Therapeutics
New Data from REZOLVE-AD Study of Rezpegaldesleukin Presented in Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting
18 days ago - By: Zacks Investment Research
- Mentions:
LLY
ANIP
ACAD
Nektar Therapeutics Q3 Loss Narrower Than Expected, Revenues Rise Y/Y
19 days ago - By: Zacks Investment Research
- Mentions:
MDWD
Nektar Therapeutics (NKTR) Reports Q3 Loss, Beats Revenue Estimates
19 days ago - By: Nektar Therapeutics
Nektar Therapeutics Reports Third Quarter 2025 Financial Results
19 days ago - By: Benzinga
- Mentions:
STVN
PODD
AMRK
SOLV
...
Earnings Scheduled For November 6, 2025
22 days ago - By: Zacks Investment Research
- Mentions:
GRDN
Guardian Pharmacy Services (GRDN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
26 days ago - By: Nektar Therapeutics
Nektar Therapeutics to Participate in the Jefferies Global Healthcare Conference in London
a month ago - By: Zacks Investment Research
- Mentions:
OABI
Nektar Therapeutics (NKTR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
a month ago - By: Nektar Therapeutics
Nektar to Announce Financial Results for the Third Quarter on Thursday, November 6, 2025, After Close of U.S.-Based Financial Markets
a month ago - By: Nektar Therapeutics
Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin Accepted for Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting
3 months ago - By: Zacks Investment Research
- Mentions:
REGN
SNY
LLY
NKTR Shares Surge 38.2% in a Week: Here's What You Should Know
3 months ago - By: Nektar Therapeutics
Nektar Therapeutics to Participate in Two Investor Conferences in September
4 months ago - By: Zacks Investment Research
- Mentions:
LLY
CRMD
IMCR
Nektar Q2 Loss Narrower Than Expected, Revenues Fall Y/Y
4 months ago - By: The Motley Fool
Nektar (NKTR) Q2 Revenue Falls 52%
4 months ago - By: Zacks Investment Research
- Mentions:
MDWD
Nektar Therapeutics (NKTR) Reports Q2 Loss, Tops Revenue Estimates
4 months ago - By: Nektar Therapeutics
Nektar Therapeutics Reports Second Quarter 2025 Financial Results
4 months ago - By: Benzinga
- Mentions:
GSAT
PGY
ADV
REAL
...
Earnings Scheduled For August 7, 2025
4 months ago - By: Zacks Investment Research
- Mentions:
RIGL
Rigel Pharmaceuticals (RIGL) Q2 Earnings and Revenues Surpass Estimates
4 months ago - By: Zacks Investment Research
- Mentions:
LLY
CRMD
AMRX
Nektar Gears Up to Report Q2 Earnings: What's in the Cards?
4 months ago - By: Zacks Investment Research
- Mentions:
DERM
Journey Medical Corporation (DERM) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
4 months ago - By: Nektar Therapeutics
Nektar to Announce Financial Results for the Second Quarter on Thursday, August 7, 2025, After Close of U.S.-Based Financial Markets
5 months ago - By: Yahoo Finance
Why Nektar Therapeutics Stock Dived by 3% Today
Please enable JavaScript to continue using this application.